Tirilazad
Alternative Names: Freedox; Tirilazad mesylate; U 74006A; U 74006F; U 74389FLatest Information Update: 19 Mar 2008
At a glance
- Originator Pfizer
- Class Pregnatrienes
- Mechanism of Action Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Subarachnoid haemorrhage
- Discontinued Craniocerebral trauma; Ischaemic heart disorders; Kidney disorders; Spinal cord injuries; Stroke; Transplant rejection
Most Recent Events
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 28 May 1999 Tirilazad has failed to gain recommendation for approval by the US FDA for the treatment of aneurysmal subarachnoid haemorrhage